Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of “Buy” by Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...
See The Best Photos Of Today’s Magnificent ‘Blood Moon’ Total Eclipse
Late on Thursday night and into the early hours of Friday, the full moon turned a beautiful reddish color as it drifted ...
IMV Europe1d
42T collaborates with Balluff and others on AI-powered line clearance system for pharma manufacturing
An automated 3D vision-guided robotic system has been developed by Goldfuß Engineering and SIMON IBV to accelerate the ...
How a canoe helped turn Hawaiian culture into a source of pride and even influenced Hollywood
Early crew members of the voyaging canoe Hokulea have gathered in Hawaii to celebrate the vessel's 50th birthday. The Hokulea ...
Space.com3d
We found 6 Easter eggs in the 'Alien: Earth' shorts revealed at SXSW 2025... at least we hope they're just Easter eggs
From malevolent computers to Arcturian shore leave, here are all the callbacks and references we spotted in these short clips.
The Engineer4d
Collaboration develops AI-powered line clearance for pharma
A ‘breakthrough approach’ for AI-powered automated line clearance in pharmaceutical manufacturing has been developed by ...
Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism
Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...
Eureka4d
42 Technology’s AI-Powered Automated Line Clearance
42 Technology has designed and built a technology demonstrator to showcase this new AI-driven system in action. It will be ...
Business Weekly5d
42 Technology and partners unveil new AI-powered pharma line clearance solution
Technology has joined forces with industry leaders in machine vision, edge AI silicon and software – Balluff, Synaptics and ...
Arcturus Therapeutics price target lowered to $68 from $74 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a ...